Jefferies valuates Bavarian Nordic's Covid-19 project

Following Bavarian Nordic's capital raising round for developing the company's Covid-19 vaccine, and its fiscal report presentation, financial analyst Jefferies is ready to start incorporating the value of the vaccine into its company valuation.

Photo: Bavarian Nordic / PR

Financial services company Jefferies now adds value to Bavarian Nordic's Covid-19 vaccine ABNCoV2 and valuates the developmental project, which was in-licensed from Adaptvac, at DKK 25 (USD 4.0) per share, according to a Friday note relating to Bavarian's financial report. According to Jefferies, this was pretty much what the analyst firm expected, especially since Bavarian had already presented its preliminary figures in January.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs